I would also be curious how this paper from 2009 a
Post# of 154975
(Total Views: 667)
Posted On: 03/12/2021 2:49:09 PM
I would also be curious how this paper from 2009 and the previous SARS outbreak plays into prior art when looking at CCR5 as a target for COVID
Toll-like receptors, chemokine receptors and death receptor ligands responses in SARS coronavirus infected human monocyte derived dendritic cells
Just out of curiosity, is Patterson patenting the use of other CCR5 antagonists for use in COVID, for example, maraviroc?
Not saying it isn't possible, but given that everyone has thrown the kitchen sink at COVID I will be very curious how the USPTO handles a patent like that. I know repurposing of existing pharmaceuticals and patents have been a mixed bag.
Also, if one can patent a company's drug for a different indication, how is an MD prescribing a drug off-label any different? For the doctor's using ivermectin off-label for COVID, can they record their results and patent ivermectin for COVID? Or any one of the 1000s of drugs the medical community has tried over the past year?
Toll-like receptors, chemokine receptors and death receptor ligands responses in SARS coronavirus infected human monocyte derived dendritic cells
Just out of curiosity, is Patterson patenting the use of other CCR5 antagonists for use in COVID, for example, maraviroc?
Not saying it isn't possible, but given that everyone has thrown the kitchen sink at COVID I will be very curious how the USPTO handles a patent like that. I know repurposing of existing pharmaceuticals and patents have been a mixed bag.
Also, if one can patent a company's drug for a different indication, how is an MD prescribing a drug off-label any different? For the doctor's using ivermectin off-label for COVID, can they record their results and patent ivermectin for COVID? Or any one of the 1000s of drugs the medical community has tried over the past year?
(1)
(0)